Our latest Neuro Pathways podcast explores observed gender differences in PD and shares how we’re using a novel female-tailored patient questionnaire to better understand the disease in women.Read More
We explain why we’ve launched an Epilepsy Precision Medicine Fellowship and how it’s designed to empower tomorrow’s epileptologists to apply neurogenetics to improve patient care
A patient presented with refractory, severe and also asymptomatic hypocalcemia at 20 weeks of gestation. Medical geneticist and nephrologist Xiangling Wang, MD, PhD, discusses management and reveals the outcome.
Interdisciplinary researchers are developing a model to predict patients’ response to costly CGRP-inhibiting monoclonal antibodies by pairing a polygenic risk score with demographic and clinical factors.
Cleveland Clinic researchers are organizing the Latino Epidemiology Cohort, a consortium that will investigate disease causes, risk and outcomes in underrepresented communities, initially focusing on Parkinson’s disease and colorectal cancer.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The tool’s utility in distinguishing Dravet syndrome from milder genetic epilepsies promises earlier intervention to attenuate risk of cognitive effects in the youngest children.
This landmark prospective investigation aims to study up to 200,000 healthy individuals over 20 years to identify brain disease biomarkers and targets for preventing and curing neurological disorders.
Our newest Neuro Pathways podcast episode spotlights advances in genomic research that show promise for targeted gene therapy for conditions from neurodegenerative diseases to epilepsy.
New virtual genomics clinic provides custom-tailored cancer treatments by targeting specific molecular alterations in patients’ tumors.
Cleveland Clinic now offers an advanced genomic testing platform as standard of care to patients with cancer. This expanded capability turns cancer treatment into a “stealth bullet” that allows clinicians to identify genetic defects and connect patients with individualized, lifesaving therapies.
A computer model developed by Cleveland Clinic oncologist Timothy Chan, MD, PhD, and colleagues accurately predicts whether immune checkpoint blockade will be effective in patients diagnosed with a wide variety of cancers.